Operator
Ladies and gentlemen, good day and welcome to Q1 FY '27 earnings conference call of Aarti Drugs Limited. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.
Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Before we begin, a brief disclaimer: this conference call contains forward-looking statements about the company, which are based on the beliefs, opinions, and expectations of the company as on date of this call.
These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. I now hand the conference over to Mr.
Adhish Patil, COO and CFO from Aarti Drugs Limited. Thank you, and over to you, Mr.
Patil.
Adhish Patil
Good morning, everyone, and thank you for joining us today for Aarti Drugs Q1 FY '27 earnings discussion. Joining me today are Mr.
Harshit Savla, Joint Managing Director;
Harshit Savla
Good morning.
Adhish Patil
Mr. Harit Shah, Whole-time Director; Mr.
Vishwa Savla, Managing Director of Pinnacle Life Science Private Limited; along with our investor relations advisors SGA. We hope you have had the opportunity to go through our financial results and investor presentation for the quarter ended 30th June 2026, which have been uploaded with the stock exchanges and are also available on our website.
Before discussing our quarterly performance, let me begin by providing some perspective on the operating environment during the quarter. The first quarter of FY '27 continued to be influenced by dynamic global landscape.
Geopolitical developments, particularly the ongoing conflict in West Asia, remained an important factor affecting international trade, logistics, and supply chains. The industry also continued to witness elevated freight costs on certain routes, longer procurement cycles in a few regions, and increased volatility in raw material prices.
At the same time, these developments created a favorable pricing environment across several API products. As availability tightened in certain markets and customer prioritized supply reliability, API prices witnessed an upward movement across the industry.
This translated into significantly better realizations for us during the quarter. While such disruptions can often create uncertainty, they also reinforce the importance of being a dependable and integrated manufacturing partner.
Customers today are increasingly looking beyond just pricing. They're placing greater emphasis on supply security, manufacturing consistency, and long-term partnerships.
These are areas where Aarti Drugs has built strong capabilities over several years, and we believe this positions us well to capitalize on evolving market opportunities. What is particularly encouraging is that despite this challenging external environment, our operations remained completely stable throughout the quarter.
We did not experience any production disruptions, material shortages, or supply-related interruptions. All our manufacturing facilities continued to operate efficiently, enabling us to meet customer commitments across both domestic and international markets without any significant delays.
This operational resilience is a direct outcome of the investments we have made over the years in strengthening our manufacturing footprint, expanding our backward integration capabilities, and maintaining disciplined inventory and procurement practices. Moving to our business performance, I'm pleased to share that we delivered a strong start to the financial year.
Our performance during the quarter was driven by a healthy combination of improved API realizations and volume growth across key products. Demand remained healthy across API and spec chem portfolio, supported by strong consumption across key therapeutic categories and continued traction in both domestic and international markets.
Our export business continued to perform well as customers increasingly sought reliable and compliant suppliers capable of ensuring uninterrupted deliveries. We also witnessed steady demand across our domestic formulations business.
Equally important, our focus on cost optimization and manufacturing efficiencies continued to yield positive results, and we witnessed improvement in EBITDA margins in Q1 FY '27. This margin expansion came despite continued pressure from higher raw material prices and elevated freight costs, highlighting the resilience of our operating model.
Our regulatory track record also continues to strengthen our competitive position. Our manufacturing facilities continue to hold approvals from leading global regulatory authorities, including the USFDA and UK regulatory agencies.
These approvals not only validate our quality systems and manufacturing standards, but also enable us to strengthen our presence in regulated markets over the long term. Another area where we continue to make steady progress is our manufacturing expansion strategy.
During Q1 FY '27, our Saykha facility continued its planned ramp-up and operated at nearly 65% utilization. This facility remains as an important strategic investment for us.
Beyond adding manufacturing capacity, Saykha strengthens our backward integration capabilities, enhances supply chain reliability, and provides us with greater control over key intermediates, especially for the antidiabetic segment. Once resolved and as utilization levels continue to improve, we expect the facility to contribute further towards operational efficiencies and long-term margin improvement.
Alongside Saykha, we are also continuing to invest in expanding our formulation business. Our brownfield expansion at the Baddi facility in the adjacent land parcel is progressing as planned.
Once completed, this project is expected to nearly double our oral solid dosage manufacturing capacity. This expansion is aligned with our long-term strategy of strengthening our formulations business, increasing manufacturing flexibility, and creating additional capacity to support future growth opportunities across both regulated, domestic, and export markets.
Overall, our capital expenditure philosophy remains disciplined and growth-oriented. Every investment that we undertake is guided by clear focus of enhancing competitiveness, improving operational efficiency, supporting backward integration, and creating long-term shareholder value.
We remain confident that these investments will provide a strong foundation for sustainable growth for the coming years. Coming to the consolidated financial highlights, Q1 FY '27's revenue stood at Rs 703.6 crores compared to Rs 590.8 crore in Q1 FY '26, reflecting a growth of 19% year-on-year.
EBITDA stood at Rs 96.9 crores versus Rs 74.7 crores in Q1 FY '26, a growth of 30% year-on-year. EBITDA margin stood at 13.8%, an expansion of 120 basis points year-on-year.
PBT stood at Rs 69.2 crores as against 51.1 crore, a growth of 35% year-on-year. PBT margin stood at 9.9%, an expansion of 120 basis points year-on-year.
PAT stood at Rs 50.1 crore as compared to 54 crore in Q1 FY '26. Q1 FY '26 PAT includes a principal tax refund of Rs 15 crore.
Excluding this, the growth in PAT would be 29% year-on-year. With respect to the standalone business highlights in Q1 FY '27, revenue stood at Rs 627.6 crores versus Rs 521.3 crores in Q1 FY '26, a growth of 20% year-on-year.
Standalone business contributed around 89% to the consolidated revenue. 68% of the standalone revenue came from the domestic market and 32% from the exports market.
Domestic revenue grew 25% year-on-year, and export revenue grew 12% year-on-year. Within the API business, the antibiotic therapeutic category contributed 35%, antiprotozoal around 18.5%, anti-inflammatory 11.9%, antidiabetic 18.2%, antifungal 10.2%, and the rest contributed around 6.1% to the total API sales.
Coming to formulation segment highlights, revenue from formulation stood at Rs 81.6 crores compared to 75.8 crores in Q1 FY '26, up 8% year-on-year. Exports contributed around 74% to this revenue.
With that, I did now like to open the floor for questions.
Operator
Thank you. We will now begin the question-and-answer session.
Anyone who wishes to ask a question may press star and one on your touchtone telephone. If you wish to remove yourself from the question queue, you may press star and two.
Participants are requested to use handsets while asking a question. Ladies and gentlemen, we'll wait for a moment while the question queue assembles.
The first question comes from the line of Avaneesh Burman from Vakharia Funds. Please go ahead.
Mr. Burman, please go ahead.
Avaneesh Burman
Can you hear me?
Adhish Patil
Yes.
Avaneesh Burman
Hello? Hello?
Adhish Patil
Yes, we can hear you.
Operator
Yes, go ahead.
Avaneesh Burman
Yeah. Adhish, I just wanted to understand how the realizations of Metformin have moved, if you can just indicate something and how on a quarter-on-quarter, on a YoY basis they have moved.
Adhish Patil
Yeah. Harit bhai, would you like to answer this question?
Harit Shah
Thanks. Yeah.
What do you mean by that, demand or the price point?
Avaneesh Burman
No, pricing movement of Metformin.
Harit Shah
Pricing movement. It has gone up by around 15% to 20% compared to before the war, 20% approximately, yes.
Adhish Patil
Yeah. Avaneesh, the year-on-year growth has been quite stark in Metformin, quite high.
The major hike came during the start of the war, around March and April. Even now, as Harit bhai pointed out, it is still higher than before, but it is slightly lower than what the price was in the month of March and April.
Avaneesh Burman
Okay. Understood.
Adhish, if you can just help understand, you are backward integrating into product and it will always give you some leverage as compared to the competition. How do you plan to use this in your let's say ambition to take market share, because as I understand it's a fairly mature molecule, the global growth rate for this product would not be very, very high.
You have aspirations to grow much faster than the industry growth. Once the backward integration is streamlined, what are the plans?
Adhish Patil
Yeah. See, as of now our Metformin capacity already is around 1,400 tonnes per month.
We are we are already utilizing it, anywhere between in mid-80s, we can say. We are expecting that, the our the demand for our Metformin will grow quite significantly in coming future due to more and more approvals which we are getting.
Avaneesh Burman
Already we have US
Adhish Patil
already we have EDQM approval for the product. In future, we are planning for USFDA as well for Metformin.
Our current plan is to scale up Metformin from 1,400 tonnes per month to roughly around 2,200 tonnes per month, out of which around 500, 550 tonnes per month could be a USFDA capacity, and rest of the capacity would be for the other other market, non-USFDA markets. Going forward, we will require lot of support from our backward integration which we have already done in Saykha.
That is why we feel that, the Saykha facility will continue to be a very important you can say area where we want to streamline our production as soon as possible and support the growth of Metformin. Metformin is already growing globally, and it's a huge market, and there is lot of potential for us to get more market share as well.
Okay.
Avaneesh Burman
By when are you expecting to supply to US market, as in when could we expect the approval to come? Yeah.
Adhish Patil
The US DMF we have already filed, so that is not a challenge. The thing is the facility, because we are constructing a fresh roughly around 500-plus tonnes per month capacity in the same you can say land parcel, in the same location.
It will take roughly around 10 10 to 12 months for that capacity to come up. Immediately as it comes up, we will file for the USFDA inspection with the help of some customers.
Okay.
Avaneesh Burman
Basically, you can't supply the API till the facility gets approval. The API supplies also at the earliest can happen only after 12 months.
Adhish Patil
Correct. 12 month It will take at least 12 months.
Currently we do have European approval for the same facility.
Avaneesh Burman
How much are you supplying to European market?
Adhish Patil
Actually it is not much. Even the European market is untapped.
Though we are trying with the smaller players right now, the key challenge what we faced so far is that many of the European clients of Metformin are also operating in the US market, they need a supplier who is both European as well as USFDA approved. That is the main reason why we are going in for USFDA approval, because that will open up not only the US market, but also the huge European markets for us as well.
Avaneesh Burman
Understood. Thank you so much.
Adhish, congratulations for the role elevation also. Many many congratulations.
Adhish Patil
Thank you.
Avaneesh Burman
Thanks, I'll get back.
Operator
Thank you. Next question comes from the line of Parth Sodha with Trinetra Asset Management.
Please go ahead.
Parth Sodha
Am I audible? Hello?
Operator
Yeah. Yes, you are.
Please go ahead.
Parth Sodha
Yes. Thank you for the opportunity.
I wanted to know do you believe the API industry has entered a sustained recovery phase, or is it still too early to call?
Adhish Patil
The thing is the war scenario, we just thought that a month back that everything streamlined and everything will come back to normal, but again the things are quite volatile as of now to say anything. The thing is certain therapeutic categories, certain products, the demand of those products behaves best when the prices are lower.
For us, frankly speaking, even if prices are lower, but if they're stable, then we can definitely make handsome margins. Competing with China was never an issue for our product line at least.
Obviously, you always face a pressure here and there little bit from certain players for certain products at a given point of time because of inventories as well, they also act up sometimes. Overall what we feel is the API business that the kind of product profile you're operating in, the business is quite stable and stable in the sense we are not that worried about Chinese competition at least.
Parth Sodha
Okay. Got it.
My second question is with the Rs 600 crore capex now completed, what is the expected asset turnover and let's say revenue contribution over next 2 to 3 years? Yeah.
Adhish Patil
The asset turns from the Phase 1 greenfield facilities is roughly around 1.5 times roughly. About Saykha, around 50% of the capacities are being captively utilized for captive consumption for our antidiabetic portfolio.
That will add to the gross margins more than the revenue itself. Having said that, the Phase 2 capex, brownfield capex, which will come in both these sites, Saykha as well as G61 in Tarapur, their asset turns would be much higher, around 3, 4 times, because most of the common facilities, like ETPs and etc., all those things are already set up and running.
All that opex and capex has already been done. The newer Phase 2 capex will give higher returns, but the one which we just did, that will get us around 1 1.5 times.
Parth Sodha
Okay. Got it.
Thank you so much for the opportunity.
Operator
Thank you. Next question comes from the line of Rashmi Shetty with Dolat Capital.
Please go ahead.
Rashmi Shetty
Thanks for the opportunity. Adhish, you mentioned that Metformin you're constructing new lines at the Saykha plant, right, for 500 to 550 tonnes in the US?
Adhish Patil
No. The Metformin expansion is being done in the same Sarigam facility where we already have around 1,400 tonnes per month.
That we'll be scaling up to around 1,700 tonnes per month, 1,700 to 1,800 1,700 tonnes per month, and additional 500 tonnes per month we'll be putting up a USFDA block in the same location. In
Rashmi Shetty
the same location. Okay.
Then what is the update on E22 plant, currently which is already USFDA approved, how many products are we supplying currently and to which markets?
Adhish Patil
Yeah. Currently, in our current USFDA plant we have two main production lines and one small product line, means the high-value products.
Currently we have around sedative, antibiotic, anti-inflammatory products which are already doing very well, and we feel that within a year's time our capacity will fall short because these products are quite big in terms of tonnage. We are also planning fresh you can say quasi-greenfield project of USFDA in the adjacent plot itself, it will have same FEIN number.
That will give us capacity enhancement of roughly slightly more than double our existing capacities. We will be putting up three more production lines to the tune of, let's say, around 10-odd tonnes per month each line, which will be a multipurpose line and from which we can cater to more products.
As of now we have around four 4, 5 products which are active from the current USFDA plant, but not all of them are going to US market. Some of them are also going to the European market.
Rashmi Shetty
Majorly all these 4 to 5 products currently we are supplying to the EU markets only, right?
Adhish Patil
Correct. Yes.
The US market still hasn't started yet, but the business development has already started, we have already sent samples also to the customers. As soon as they get the approval for vendor addition, then we can start the supplies.
Rashmi Shetty
Okay. At your Saykha plant, in your greenfield plant, specialty chemical products are also manufactured, right?
Adhish Patil
In Saykha, yes.
Rashmi Shetty
Your growth for the specialty chemical was around 149%, the sales were around Rs 82 crores. Is it because of this new plant which has come up and we have supplied newer products?
Basically, how should we look at it for the full year? Is it going to contribute significantly this year?
Yeah.
Adhish Patil
This first quarter's performance will definitely repeat for the next three quarters. In fact, we will be trying to improve it further.
The answer to your question was yes, it is because of that Saykha facility which we have just put up.
Rashmi Shetty
How many tonnes per month we have reached for this spec chem business in Saykha plant?
Adhish Patil
For Saykha, for the methylamine plants, we have already reached around 65% utilization. There are few other products where the utilization is lower, there we are trying to improve, but methylamines, the main gases, that we already reached around 64%, 65% in the quarter of June.
Rashmi Shetty
That comes to how many tonnes per month?
Adhish Patil
I'll tell you. It is roughly around 60 tonnes per day.
For the entire quarter, it was somewhere around 3,500 tonnes for entire quarter, June quarter.
Rashmi Shetty
Okay. For this year, basically this will be the new quarterly run rate for the specialty chemicals if you want to model in our Correct.
in our Correct, okay. Related to your Tarapur facility, where are we currently for the salicylic acid supplies?
Adhish Patil
Yeah. The improvement is still awaited in that facilities.
Last quarter, in fact, we kept the production of salicylic acid very, very low. In fact, the entire quarter we produced only 67 tonnes of salicylic acid.
One of the main reasons was we were waiting for that equipment which came and it is installed now. The main purpose was to further reduce the raw material costing and also improve the effluent quality from the salicylic acid.
Plus we just commissioned the plant for manufacturing derivative of salicylic acid, that is methyl salicylate and few other salicylates can also be manufactured because it is a multipurpose plant. That capacity is roughly around 350, 400 tonnes per month.
The trial batches have started. We got around 5, 10 tonnes of production, trial production, and we will be ramping it up soon.
What we'll be trying to do is that produce the salicylic acid and then convert it into the derivatives and then sell it to the market, because that will reduce our losses. Unfortunately, what has happened to the anti-dumping duty part, it got delayed a little bit.
Though the case was okay, but the government asked that the injury period should be a year more. We'll have to wait most probably one more year for anti-dumping duty to come up.
We are pretty much sure that it will come for salicylic acid. Till that point of time, I think it will be better for us that we manufacture the derivative of salicylic acid and then sell it to the market, because then at least we will try to achieve breakeven for that location.
Rashmi Shetty
Okay. Generally margins are higher in derivatives of salicylic acid compared to the plain product?
Adhish Patil
Yeah. What happened was before we started the production, salicylic acid itself had very high margins, and derivatives also had a decent margin, but then the thing is for derivatives you have to venture it into 4, 5 products, whereas salicylic acid you can just get all that margin in one product itself.
That was the initial plan that to manufacture salicylic acid and supply that to the Indian consumers. Then after we launched the capacity, Chinese players, they drastically dropped the pricing of salicylic acid mainly to drive the competition out, that is the main purpose.
Because of that, salicylates became more attractive than the salicylic acid itself because of that price drop. Initially it was not like that, but as of now it is salicylates are more profitable than salicylic acid.
Rashmi Shetty
Okay. My last question is on volume growth and price growth for this quarter, and also if you can give an outlook on that for the remaining three quarters.
Adhish Patil
Yeah. Most of the volume growth has come from the spec chem.
Overall company level, we still achieved around 3.5% aggregate volume growth for both domestic and local markets, but majority of the growth came from the price growth in the June quarter. The main reason for this is because there were sudden price hikes because of the raw material prices went up due to that US-Iran war.
Because of such sharp increase in the prices, typically what happens is formulation purchasers, they refrain from buying too much, they keep the stock to building because the prices are very high. The quantity sales goes down in such scenario.
Still we were able to achieve 3.5% growth, but mainly it was driven by the price. As of now, the pricing has eased out as compared to the month of March and April.
It came down slowly from April, May, and now. Still the prices are high because still the war restarted and we are not sure how long it will now get stretched.
Rashmi Shetty
On YoY basis, what was the pricing growth in absolute terms?
Adhish Patil
In YoY basis, at the aggregate level, we saw somewhere around 16%, 17% aggregate growth.
Rashmi Shetty
You feel that this will not be sustainable, right, because structurally there is not easing in the pricing pressure?
Adhish Patil
Right now, again the pressure is still there, but as everything eases out, then when the raw material prices goes down, then probably the selling prices will come down.
Rashmi Shetty
Okay. What is the outlook for the remaining three quarters in terms of volume growth and price growth?
How do you see any guess estimates?
Adhish Patil
Action speaking, we are hoping that volume growth should be much better than June quarter because June quarter there was sudden hike in the prices. As I said, the demand got affected because of that.
When the price stays high for a longer period of time, then the demand should come back. Once the inventory levels at the further end of the value chain goes down, the demand should come back.
Export demand won't get impacted much. It is generally the domestic demand what we have observed in past as in 3, 4 years back that in the very high prices scenario, certain categories of products, like mostly antibiotics and some antidiarrheals, they face demand pressure.
Rashmi Shetty
Got it. Thank you and congratulations on your new role.
Adhish Patil
Thank you.
Operator
Thank you so much. Thank you.
Next question comes from the line of Dhwanil Desai with Turtle Capital. A reminder to all the participants that you may press star and one to ask a question.
Mr. Desai, please go ahead.
Dhwanil Desai
Yeah. Good morning, Adhish.
Am I audible?
Adhish Patil
Yes.
Dhwanil Desai
Yeah. Adhish, the first question is you talked about the volatility on the pricing side of it, the realization part of it.
Now I think even when this price increase was not there, our eventually goal was to reach to 14%, 15% EBITDA margin in due course. If once the realization comes down, the war settles down and the realization and RM both comes down, do you think we are on part to reach 15% margin maybe by end of this year, or is that a longer journey?
Adhish Patil
Yeah. This quarter also we took some write-offs of means aging capital WIP, but that way means we had crossed around 14% EBITDA margin in Q1 as well at consolidated level.
So 14% is quite doable. Means we are almost there, almost there.
Now once the utilization of the exist the two main greenfield projects what we have put up, once that improves, then definitely 15% is, should be very easy once once the salicylic acid plant comes on track. Then that drag will ease on the overall P&L.
So 14% so above 14% we are we are almost there already, I would say.
Dhwanil Desai
Right. Then the realization may not stay at the same level, right, it will come down.
That means that the 14% that we see today in Q1 eventually may ease out as the prices come down. Is that a fair way to think?
Adhish Patil
In short run, yes. Then what will happen, ideally the volume growth should pick up once the pricing goes down, because our March quarter volumes were much higher than our June quarter.
Overall, we're almost there. I will still say we are almost there.
In the quarter of December and March, the main thing was our Saykha plant was also not operational fully. The utilization was much lower, 30% and 40% respectively.
This is the first quarter that utilization went above 60%. That is also one of the reasons why the EBITDA margins have gone up a little.
Dhwanil Desai
Okay. Got it.
Second question, Adhish, is that we have done a very large capex in last 2 years across various products. Based on that, our aspiration of double-digit volume growth or maybe 15% volume growth, should that be the base?
Because 7%, 8% volume growth anyways we were clocking even without capex, right? All these new products and new capex coming into play, are we aiming for 15% kind of a volume growth, or you think it will be more closer to high single-digit, low double-digit kind of a number?
Adhish Patil
Yeah. The thing is, for next 2 years we are very well poised for that 10% to 15% kind of a volume growth, because right now, even if I consider salicylic acid's capacity as just 600 tonnes per month, we are sitting roughly at around 70% utilization, mainly on the account of that project.
There is lot of scope for existing products as well as this a bit in the Saykha facility and a lot in salicylic facility. Capacities are there.
Achieving 10% to 15% volume growth in next 2 years should not be a problem. Only challenge would be how fast we streamline the salicylic acid and the derivative part.
Dhwanil Desai
Okay. If the salicylic acid part, let's say if we assume that until the anti-dumping duty comes into play, let's worst case maybe even the derivative part doesn't pick up, then without that is it possible to get to that 10%, 12% volume growth?
Adhish Patil
Still 10% should be doable.
Dhwanil Desai
Okay. Got it.
If you can help us understand the mix how it has progressed over time between let's say regulated and unregulated market. I think Europe was quite small for us, US was almost nonexistent, which are generally better realization markets.
How it has progressed for us and how do you see that going forward now that the USFDA thing at least for one plant is in place?
Adhish Patil
Yes. Yes, that is one of the key focus area for us going forward, that how to increase our regulated market share.
Definitely getting USFDA approval for API facility after a long wait of 10 years, now that scope has opened up for us not only for US, but for Europe market as well. Plus we got for European markets for nine products.
As I was speaking before that, we are already filed for some of them to be shifted to a bigger WHO kind of a GMP plant, which will be transforming to the EDQM approved plant. Our cost structure will go down, the pricing will go up, there will be expansion in the margin.
Plus we'll get more volumes also because of this newer European markets. Plus other than that, we have also got all regulatory approvals for our formulations business as well.
We got USFDA approval for the oncology. We also got European approval for the oral solid dosage.
There also we are filing a lot for regulated markets. Already formulation has demonstrated that we are doing more than 70% of our formulation business in export market now.
We are tapping the regulated markets in that division as well. Both in formulation as well as in APIs, we are targeting regulated markets.
Having said that, I would say that still the current sales doesn't reflect that profitability which will come through regulated market. It is still in the business development phase.
Some success we got, but then as the pie becomes meaningful, then it will meaningfully reflect in the overall EBITDA margins of the company.
Dhwanil Desai
Got it. Thank you.
That's it.
Operator
Hello. Thank you.
Next question comes from the line of Sajal Kapoor with Antinvest Value Thinking. Please go ahead.
Mr. Kapoor, please go ahead.
Sajal Kapoor
Thank you for the opportunity. Hi.
Yeah. Hi.
I can hear you. The question is how much of Saykha's benefit is visible in revenue today, and how much is invisible because it replaces intermediates that were previously procured externally?
Adhish Patil
Yeah. I would say the last quarter was still around 60%, 70% we must have procured from outside last quarter, in the June quarter.
Already that percentage has gone down drastically in this quarter. Increasingly in September quarter and then by December quarter, I think hopefully around 80%, 90% of the captive consumption will happen through Saykha plant.
Though we will always need to keep around 10% external supplies for diversification case, but yeah, in September quarter and December quarter, the captive consumption will go up drastically as compared to June quarter.
Sajal Kapoor
Adhish, the question really is the captive consumption should improve our gross margins, right? Because it's a backward integration, it gives us not only more control of the value chain, but it also makes in the eyes of the customer, it makes us as a source more secure because we are not reliant on external.
Yes, 10% is fine for the sake of diversification. Gross margins, what's your take on the gross margins as utilization improves beyond 65% where we are today to, let's say, reaching closer to 90%?
Adhish Patil
We're hoping that it should add another percent also in the gross contribution at the peak level.
Sajal Kapoor
Right. That gross contribution coupled with better utilization of the network should naturally improve the EBITDA margins.
I think the other participants' question was also along the same lines, exploring how soon or when we can get back to 15%. Those two things put together, improving gross margins and improving utilization, should result in a much better EBITDA margins.
It could even be 200 basis point improvement, no?
Adhish Patil
In the current condition, yes. Then what happened in June quarter was because of that ammonia shortages and the derivative compound shortages, the prices had gone up quite drastically for this chain of products.
Once it settles down, we need to see whether 200% will come or not. 200, 200 basis points will come or not.
Sajal Kapoor
Sure. That's all.
Thank you so much. Thank you.
Adhish Patil
Okay. Thank you.
Thank you.
Operator
Thank you. Ladies and gentlemen, as there are no further questions, we have come to the end of question-and-answer session.
I would now like to hand the conference over to the management for closing comments.
Adhish Patil
Our diversified presence across APIs, formulations, and specialty chemicals, together with our long-standing customer relationships and broad product portfolio, along with our ongoing investments in capacity expansion and operational excellence, we believe we are well positioned to capture this opportunities and sustain our growth momentum in the years ahead. Thank you once again for your continued support and confidence in Aarti Drugs.
For any further questions, please reach out to SGA, our investor relations advisors. Thank you so much, and have a nice day.
Operator
Thank you for attending Aarti Drugs Limited conference call. Thank you for participation.
You may now disconnect. The conference has now concluded.
Sajal Kapoor
Thank you.
Already premium?